Health Care Related Organization – Page 105

AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD

2 years ago talkbio0Tagged Approved, AstraZeneca, Autoimmune Diseases, dosing, Infrequent, Long-acting C5 complement inhibitor, Neuromyelitis Optica, Rating (action), ravulizumab-cwvz, Reduced, Relapse, Ultomiris, United States Food and Drug Administration, With frequency

AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency

Roche’s Phase III Trial Success with IL-6 Blocker Enspryng Tempered by Modest Outcomes

2 years ago talkbio0Tagged Blocker, disappointment, Enspryng, Expectations, interleukin-6, Myasthenia Gravis, Generalized, Phase 3 Clinical Trials, Roche (company), satralizumab

Roche, IL-6 blocker, Enspryng (satralizumab), Phase III trial, Generalized Myasthenia Gravis (gMG), Disappointment, Expectations

Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion

2 years ago talkbio0Tagged Biologics Manufacturing Site, California, Capacity, CDMOs, Contract Development, genentech, Global Biologics Market, Growth, Large-Scale Commercial Mammalian Products, Lonza, manufacturing organizations, Roche (company), utilization qualifier, Vacaville

Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth

AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

2 years ago talkbio0Tagged AstraZeneca, Evaluation, Inhaler, Prices, SmithKline Beecham

Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices

Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline

2 years ago talkbio0Tagged Backed, Contineum, IPO, Johnson and Johnson, Multiple Sclerosis, Phase 2 Clinical Trials, PIPE-307, Public Offering

Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307

Pfizer Reduces Stake in Haleon, Raising Over $2 Billion in Share Selloff

2 years ago talkbio0Tagged Consumer Health Spinoff, Debt Management, Haleon, Pfizer, Stake Reduction, Strategic Focus

Pfizer, Haleon, Consumer Health Spinoff, Share Selloff, Stake Reduction, GSK, Debt Management, Strategic Focus

Boehringer Ingelheim and Sosei Sign Potential $732 Million Collaboration for Schizophrenia Treatment

2 years ago talkbio0Tagged boehringer ingelheim, cellular targeting, GPR52 gene, Partnership, portfolio, Schizophrenia, Sosei

Boehringer Ingelheim, Sosei, Schizophrenia Treatment, Partnership, $732 Million Deal, GPR52 Targeting Portfolio

FDA Unexpectedly Postpones Approval Decision for Eli Lilly’s Donanemab, Schedules AdComm Review

2 years ago talkbio0Tagged Accelerated Approval, Aduhelm, Anticipated, Approved, aspects of adverse effects, Central Nervous System Agents, Cerebral Edema, Clinical Trials, Deferred, Donanemab, Effectiveness, eli lilly, Full approval, Hemorrhage, Leqembi, PCNS, Peripheral, precedent, Review [Publication Type], Safety, United States Food and Drug Administration

Donanemab, Eli Lilly, FDA delay, Approval postponement, Peripheral and Central Nervous System Drugs Advisory Committee (PCNS), Safety and efficacy review, Clinical trial results, Brain swelling and bleeding side effects, Accelerated approval declined, Leqembi and Aduhelm precedent, Full approval anticipated, Accelerated approval rejected.